Vicore Pharma Holding AB
STO:VICO

Watchlist Manager
Vicore Pharma Holding AB Logo
Vicore Pharma Holding AB
STO:VICO
Watchlist
Price: 7.91 SEK 1.67% Market Closed
Market Cap: 1.9B SEK
Have any thoughts about
Vicore Pharma Holding AB?
Write Note

Vicore Pharma Holding AB
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Vicore Pharma Holding AB
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Vicore Pharma Holding AB
STO:VICO
EPS (Diluted)
-kr1
CAGR 3-Years
16%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
EPS (Diluted)
kr3
CAGR 3-Years
22%
CAGR 5-Years
8%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
EPS (Diluted)
kr1
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
EPS (Diluted)
-kr28
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
EPS (Diluted)
kr10
CAGR 3-Years
1%
CAGR 5-Years
3%
CAGR 10-Years
N/A
BioArctic AB
STO:BIOA B
EPS (Diluted)
kr2
CAGR 3-Years
N/A
CAGR 5-Years
-10%
CAGR 10-Years
N/A
No Stocks Found

Vicore Pharma Holding AB
Glance View

Market Cap
1.9B SEK
Industry
Biotechnology

Vicore Pharma Holding AB is a pharmaceutical company, which engages in the development of drugs with focus on interstitial lung diseases and related indications. The company is headquartered in Goeteborg, Vastra Gotalands. The company went IPO on 2015-12-10. The firm's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The firm is a wholly owned subsidiary of Mintage Scientific AB.

VICO Intrinsic Value
2.94 SEK
Overvaluation 63%
Intrinsic Value
Price

See Also

What is Vicore Pharma Holding AB's EPS (Diluted)?
EPS (Diluted)
-1.7 SEK

Based on the financial report for Jun 30, 2024, Vicore Pharma Holding AB's EPS (Diluted) amounts to -1.7 SEK.

What is Vicore Pharma Holding AB's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
2%

Over the last year, the EPS (Diluted) growth was 46%. The average annual EPS (Diluted) growth rates for Vicore Pharma Holding AB have been 16% over the past three years , 2% over the past five years .

Back to Top